{"entity":{"id":"alfredo-addeo","kind":"person","name":"Alfredo Addeo","aka":[],"tldr":"Thoracic oncologist who heads the Oncology Division at Geneva University Hospitals.","summary":"Alfredo Addeo is Head of the Oncology Division at Geneva University Hospitals (HUG). A medical oncologist specialising in thoracic oncology and immunotherapy, he has published widely on immune checkpoint inhibitors, biomarkers of response and the design of clinical trials in non-small-cell lung cancer, small-cell lung cancer and mesothelioma. His papers include the SAKK 19/17 safety analysis of first-line durvalumab in PD-L1 positive advanced non-small-cell lung cancer in patients with a performance status of 2, a Swiss cohort study of immune checkpoint inhibitors in relapsed small-cell lung cancer, and a French-language review on whether to treat elderly patients with metastatic non-small-cell lung cancer with immunotherapy. He leads the division's clinical and research work in Geneva.","asOf":"2026-09-10","links":[{"label":"Institution profile","url":"https://www.hug.ch/en/oncology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Addeo+A%5BAuthor%5D"}],"tags":["leadership","clinician-scientist","lung cancer","immunotherapy"],"related":[],"cancers":["nsclc","sclc","mesothelioma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":["hug-geneva"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["cancer-immunology-immunotherapy"],"dependsOn":[],"notes":[],"role":"Head of Division, Oncology","institutionId":"hug-geneva","specialisms":["Thoracic oncology","Immunotherapy","Medical oncology"],"profiles":[{"label":"Institution profile","url":"https://www.hug.ch/en/oncology"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Addeo+A%5BAuthor%5D"}],"papers":[{"title":"SAKK 19/17: safety analysis of first-line durvalumab in patients with PD-L1 positive, advanced nonsmall cell lung cancer and a performance status of 2","journal":"Cancer Immunology, Immunotherapy","year":2020,"doi":"10.1007/s00262-020-02757-8"},{"title":"Cancer du poumon non à petites cellules métastatique du sujet âgé et immunothérapie. Traiter ou s’abstenir?","journal":"Revue Médicale Suisse","year":2025,"doi":"10.53738/revmed.2025.21.918.47231"},{"title":"Outcomes with immune checkpoint inhibitors for relapsed small-cell lung cancer in a Swiss cohort","journal":"Cancer Immunology, Immunotherapy","year":2020,"doi":"10.1007/s00262-020-02565-0"}]},"route":"/people/alfredo-addeo/","neighbours":{"cancer":[{"id":"mesothelioma","kind":"cancer","name":"Mesothelioma","route":"/cancers/mesothelioma/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"institution":[{"id":"hug-geneva","kind":"institution","name":"Geneva University Hospitals (HUG)","route":"/institutions/hug-geneva/"}],"journal":[{"id":"cancer-immunology-immunotherapy","kind":"journal","name":"Cancer immunology, immunotherapy","route":"/journals/cancer-immunology-immunotherapy/"}]}}